Her2-BATS and Pembrolizumab in Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Metastatic Breast Cancer
Related studies linked through entity extraction aliases.
Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone: A Whole Body MRI Study
- Status
- UNKNOWN
- Phase
- NA
SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Understanding Value in Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Halaven Patient Registry (Metastatic Breast Cancer, MBC)
- Status
- UNKNOWN
- Phase
- N/A
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO
- Status
- COMPLETED
- Phase
- PHASE2
Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- NA
Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC
- Status
- COMPLETED
- Phase
- PHASE2
PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- N/A
Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE1
Palbociclib After CDK and Endocrine Therapy (PACE)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide
- Status
- COMPLETED
- Phase
- PHASE2
Metastatic Breast Cancer Treatment Planning
- Status
- WITHDRAWN
- Phase
- NA
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
- Status
- COMPLETED
- Phase
- PHASE3